Comparative Pharmacology
Head-to-head clinical analysis: CANTIL versus HICON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANTIL versus HICON.
CANTIL vs HICON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CANTIL (mepenzolate bromide) is a quaternary ammonium anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing gastrointestinal motility and gastric acid secretion.
Unknown; possibly involves modulation of hypothalamic thermoregulatory center.
50 mg orally three times daily, may increase to 100 mg three times daily if needed
HICON (norepinephrine) 0.05-0.5 mcg/kg/min IV continuous infusion, titrated to blood pressure.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours; clinically, this supports twice-daily dosing in patients with normal renal function.
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Primarily renal excretion of unchanged drug and metabolites; approximately 60-70% eliminated renally, with about 30-40% excreted in feces via biliary elimination.
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Category C
Category C
Anticholinergic / Antispasmodic
Anticholinergic